
Cornelis Smit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3045498/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen. Clinical Pharmacokinetics, 2022, 61, 123-132.	1.6	7
2	Optimizing moxidectin dosing for <i>Strongyloides stercoralis</i> infections: Insights from pharmacometric modeling. Clinical and Translational Science, 2022, 15, 700-708.	1.5	10
3	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. Clinical Pharmacokinetics, 2022, 61, 1167-1175.	1.6	9
4	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years. AAPS Journal, 2021, 23, 53.	2.2	12
5	Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. Archives of Disease in Childhood, 2021, , archdischild-2020-321381.	1.0	4
6	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clinical Infectious Diseases, 2020, 70, 2213-2215.	2.9	16
7	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. British Journal of Clinical Pharmacology, 2020, 86, 303-317.	1.1	37
8	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. Journal of Antimicrobial Chemotherapy, 2020, 75, 3286-3292.	1.3	9
9	Implications for IV posaconazole dosing in the era of obesity. Journal of Antimicrobial Chemotherapy, 2020, 75, 1006-1013.	1.3	18
10	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. Clinical Pharmacokinetics, 2020, 59, 659-669.	1.6	50
11	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharmaceutical Research, 2019, 36, 112.	1.7	13
12	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. Clinical Pharmacokinetics, 2019, 58, 1333-1343.	1.6	11
13	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. Journal of Antimicrobial Chemotherapy, 2019, 74, 978-985.	1.3	23
14	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 275-285.	1.5	135
15	Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. Journal of Comparative Effectiveness Research, 2018, 7, 561-567.	0.6	3
16	Efficient Synthesis and Applications of Peptides containing Adenylylated Tyrosine Residues. Angewandte Chemie - International Edition, 2011, 50, 9200-9204.	7.2	21